221 related articles for article (PubMed ID: 26492090)
1. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
Freyer G; Isambert N; You B; Zanetta S; Falandry C; Favier L; Trillet-Lenoir V; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Fumoleau P
Br J Cancer; 2012 Aug; 107(4):598-603. PubMed ID: 22790797
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
8. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Khayat D; Tejpar S; Spano JP; Verslype C; Bloch J; Vandecaveye V; Assadourian S; Soussan-Lazard K; Cartot-Coton S; Van Cutsem E
Eur J Cancer; 2013 Mar; 49(4):790-7. PubMed ID: 23312881
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies.
Doi T; Boku N; Onozawa Y; Takahashi K; Kawaguchi O; Ohtsu A
Invest New Drugs; 2020 Oct; 38(5):1390-1399. PubMed ID: 31907738
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.
Sunakawa Y; Takahashi K; Kawaguchi O; Yamamoto N
Invest New Drugs; 2022 Oct; 40(5):1032-1041. PubMed ID: 35771301
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
[TBL] [Abstract][Full Text] [Related]
17. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
Diaz-Padilla I; Siu LL; San Pedro-Salcedo M; Razak AR; Colevas AD; Shepherd FA; Leighl NB; Neal JW; Thibault A; Liu L; Lisano J; Gao B; Lawson EB; Wakelee HA
Br J Cancer; 2012 Aug; 107(4):604-11. PubMed ID: 22805331
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
